公开(公告)号：US20220275103A1

公开(公告)日：2022-09-01

申请号：US17746569

申请日：2022-05-17

申请人： CENTRICSBIO, INC.

发明人： Jaewon JEON ,  Haneul KIM ,  Suin LEE ,  Woochang KIM

IPC分类号： C07K16/28 ,  A61P35/00

摘要： The present disclosure relates to an anti-CD300c monoclonal antibody and its use for preventing or treating cancer. The anti-CD300c monoclonal antibody according to the present disclosure binds to a CD300c antigen with high specificity and also promotes anticancer immune responses. Thus, this anti-CD300c monoclonal antibody is expected to be effectively used against growth, development, metastasis, and the like of various cancer

公开(公告)号：US20220305082A1

公开(公告)日：2022-09-29

申请号：US17826954

申请日：2022-05-27

申请人： CentricsBio, Inc.

发明人： Jaewon JEON ,  Haneul KIM ,  Suin LEE

IPC分类号： A61K38/17 ,  C07K14/725 ,  A61K35/15 ,  A61K35/17 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

摘要： A chimeric antigen receptor that specifically binds to a CD300c antigen or a receptor thereof, immune cells expressing the same, and uses thereof are disclosed. The chimeric antigen receptor that specifically binds to a CD300c antigen or a receptor thereof is able to specifically recognize cancer cells expressing the CD300c antigen or the CD300c receptor so that growth, metastasis, development, and the like of cancer can be suppressed in a direct and effective manner. Thus, it is expected that the chimeric antigen receptor can be effectively used as an immunotherapeutic agent for various cancers.

公开(公告)号：US20240254220A1

公开(公告)日：2024-08-01

申请号：US18290409

申请日：2022-05-13

申请人： CentricsBio, Inc.

发明人： Jae-Won JEON ,  Suin LEE ,  Haneul KIM ,  Chang Ki LIM

IPC分类号： C07K16/28 ,  A61K31/337 ,  A61K31/44 ,  A61K31/7068 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  G01N33/574

CPC分类号： C07K16/2803 ,  A61K31/337 ,  A61K31/44 ,  A61K31/7068 ,  A61K39/3955 ,  A61P35/00 ,  G01N33/57492 ,  A61K2039/505

摘要： Disclosed are an anti-CD300c antibody and a combined therapy thereof and, more specifically, a pharmaceutical composition, a kit, and a method for the prevention or treatment of cancer, each of which comprises, as active ingredients, an anti-CD300c monoclonal antibody and at least one additional anticancer agent.